JP6449773B2 - Ophthalmic composition for anionic soft contact lenses - Google Patents

Description

  The present invention relates to an ophthalmic composition for an anionic soft contact lens that can suppress the adsorption of pranoprofen and / or a salt thereof to the anionic soft contact lens. The present invention also relates to a method for suppressing adsorption of pranoprofen and / or a salt thereof to an anionic soft contact lens.

  In recent years, soft contact lenses (hereinafter sometimes abbreviated as SCL) that can be worn continuously or for a long time have been developed, and the number of SCL wearers is increasing. Conventionally, SCL has been developed that exhibits various surface characteristics such as anionic, zwitterionic, and nonionic, but anionic SCL is superior in oxygen permeability and has a low burden on the cornea. It has advantages and has been widely used in recent years. Therefore, in order to improve the convenience of the anionic SCL wearer, an eye drop that can be used in the state where the anionic SCL is worn (an eye drop for an anionic SCL) is required.

  In addition to exerting the desired medicinal effect, the SCL eye drops need to be formulated so as not to adversely affect SCL. In particular, when a drug in an eye drop for SCL is adsorbed to SCL, the lens is deformed, the feeling of use is decreased, and the desired pharmacological effect may not be exerted on the ocular mucosa. In the drug formulation design, suppression of drug adsorption on SCL is a particularly important issue. In addition, since the drug adsorption characteristics vary depending on the surface characteristics of SCL, it is necessary to design the eye drops for SCL according to the applied SCL material.

  On the other hand, pranoprofen and / or its salts have the effect of suppressing the biosynthesis of prostaglandins that cause inflammation and pain. In the ophthalmology field, alleviation of symptoms such as redness and itching of the eyes, and blepharitis It is widely used for the purpose of prevention or treatment of conjunctivitis, scleritis including episclitis, postoperative inflammation, anterior uveitis, etc. Several preparation techniques for eye drops for SCL containing pranoprofen and / or a salt thereof have also been reported. For example, Patent Document 1 discloses that an ophthalmic composition for nonionic silicone hydrogel contact lenses containing vitamin A and taurine can suppress lipid adsorption on the surface of nonionic silicone hydrogel contact lenses. ing. However, Patent Document 1 does not discuss adsorption of pranoprofen to SCL, nor does it disclose a technique applicable to anionic SCL.

  Conventionally, a formulation technique for suppressing the adsorption of a drug to SCL has also been studied. For example, Patent Document 2 discloses (A) a basic drug selected from amines having secondary amino groups and / or tertiary amino groups, and salts thereof; and (B) amino acids and salts thereof, acidic mucopolysaccharides and their It is disclosed that a composition for soft contact lenses containing a salt and one or more selected from cyclodextrins and having a pH of 3.5 to 4.8 can suppress adsorption of a basic drug to SCL. ing. However, in Patent Document 2, no study has been made on the suppression of adsorption of pranoprofen to anionic SCL, and the pH must be set to 3.5 to 4.8. There is also a problem in terms of restrictions.

JP 2011-111425 A International Publication No. 2007/77783

  Conventionally, attention has been paid to pranoprofen and / or a salt thereof, and no study has been made on its adsorption property to anionic SCL. Under such circumstances, the present inventor confirmed that the anionic SCL has higher adsorptivity of pranoprofen and / or its salt than the nonionic SCL (see Test Example 1 described later). ). Therefore, in order to put an ophthalmic composition for anionic SCL containing pranoprofen and / or a salt thereof into practical use, a formulation technique capable of suppressing the adsorption of pranoprofen and / or a salt thereof to anionic SCL. The establishment of is urgently needed.

  Therefore, the present invention provides a technique for suppressing adsorption of pranoprofen and / or a salt thereof to anionic SCL in an ophthalmic composition for anionic SCL containing pranoprofen and / or a salt thereof. For the purpose.

  The present inventor has intensively studied to solve the above problems, and in the ophthalmic composition for anionic SCL containing pranoprofen and / or a salt thereof, taurine and / or a salt thereof is contained, and It has been found that by setting the pH to 7.7 or less, adsorption of pranoprofen and / or a salt thereof to anionic SCL can be effectively suppressed. Furthermore, it has also been found that a clear appearance can be realized by setting the pH of the anionic SCL ophthalmic composition to 5.5 or higher. The present invention has been completed by further studies based on this finding.

That is, this invention provides the invention of the aspect hung up below.
Item 1. An anion comprising pranoprofen and / or a pharmaceutically acceptable salt thereof, taurine and / or a pharmaceutically acceptable salt thereof, and having a pH of 7.7 or less Composition for sexual soft contact lenses.
Item 2. Item 5. The ophthalmic composition for an anionic soft contact lens according to Item 1, having a pH of 5.5 to 7.7.
Item 3. Item 3. The ophthalmic composition for an anionic soft contact lens according to Item 1 or 2, wherein taurine and / or a pharmaceutically acceptable salt thereof is contained in an amount of 0.01 to 3 w / v%.
Item 4. Item 4. The ophthalmic composition for an anionic soft contact lens according to any one of Items 1 to 3, wherein pranoprofen and / or a pharmaceutically acceptable salt thereof is contained in an amount of 0.001 to 0.5 w / v%.
Item 5. Item 5. An ophthalmic composition for an anionic soft contact lens according to any one of Items 1 to 4, which is an eye drop for an anionic soft contact lens.
Item 6. In an ophthalmic composition for anionic soft contact lenses containing pranoprofen and / or a pharmaceutically acceptable salt thereof, taurine and / or a pharmaceutically acceptable salt thereof is blended, and the pH is set to 7. A method for suppressing adsorption of pranoprofen and / or a pharmaceutically acceptable salt thereof to an anionic soft contact lens, characterized by adjusting to 7 or less.
Item 7. Anionic soft contact of a liquid preparation containing pranoprofen and / or a pharmaceutically acceptable salt thereof and taurine and / or a pharmaceutically acceptable salt thereof and having a pH of 7.7 or less Use for the production of ophthalmic compositions for lenses.
Item 8. A solution containing pranoprofen and / or a pharmaceutically acceptable salt thereof and taurine and / or a pharmaceutically acceptable salt thereof and having a concentration of 7.7 or less is applied to an anionic soft contact lens. A method for suppressing adsorption of pranoprofen and / or a pharmaceutically acceptable salt thereof to an anionic soft contact lens, comprising a step of contacting.

  According to the ophthalmic composition for anionic SCL of the present invention, the adsorption of pranoprofen and / or a salt thereof to the anionic SCL can be suppressed, so that the planopro without adversely affecting the anionic SCL. The medicinal effects of phen and / or a salt thereof can be effectively exhibited. Further, according to the ophthalmic composition for anionic SCL of the present invention, taurine and / or a salt thereof not only suppresses the adsorption of pranoprofen and / or a salt thereof to anionic SCL, Since the metabolism promoting effect is also exhibited, it is possible to achieve an excellent eye disease prevention and recovery effect in combination with the medicinal effects of pranoprofen and / or a salt thereof.

  In addition, by setting the pH to 5.5 or more in the ophthalmic composition for anionic SCL of the present invention, white turbidity caused by pranoprofen and / or a salt thereof can be suppressed, and a clear appearance property It is possible to provide an ophthalmic composition for anionic SCL exhibiting In the present specification, “clear” refers to a state in which white turbidity is not caused by pranoprofen and / or a salt thereof, and is not limited to colorless and clear, but is colored and clear that is colored by other components. It is a concept that also includes.

1. Ophthalmic Composition for Anionic SCL The ophthalmic composition for anionic SCL of the present invention comprises pranoprofen and / or a pharmaceutically acceptable salt thereof, taurine and / or a pharmaceutically acceptable salt thereof. It is characterized by containing a salt and having a pH of 7.7 or less. Hereinafter, the ophthalmic composition for anionic SCL of the present invention will be described in detail. In the present specification, “an ophthalmic composition for an anionic SCL” refers to a composition used in an ophthalmic field and used in a form of being in contact with an anionic SCL. In the present specification, the unit of concentration of each component “w / v%” indicates mass to volume percentage and is synonymous with g / 100 mL.

  The ophthalmic composition for anionic SCL of the present invention contains pranoprofen and / or a salt thereof. Planoprofen is also known as α-methyl-5H- [1] benzopyrano [2,3-b] pyridine-7-acetic acid, and is a known compound known to have anti-inflammatory activity in the ophthalmic field. .

  The salt of pranoprofen is not particularly limited as long as it is pharmaceutically acceptable. For example, metal salts such as sodium salt, potassium salt, calcium salt, magnesium salt, aluminum salt; triethylamine salt, diethylamine salt, Examples thereof include organic base salts such as morpholine salt and piperazine salt. These pranoprofen salts may be used alone or in combination of two or more.

  In the ophthalmic composition for anionic SCL of the present invention, one kind selected from pranoprofen and a salt thereof may be used alone, or two or more kinds may be used in combination. Of the pranoprofen and salts thereof, pranoprofen is preferable.

  In the ophthalmic composition for anionic SCL of the present invention, the concentration of pranoprofen and / or a salt thereof is appropriately set according to the use of the ophthalmic composition for anionic SCL. 0.001-0.5 w / v%, preferably 0.01-0.2 w / v%, more preferably 0.01-0.1 w / v%.

  The ophthalmic composition for anionic SCL of the present invention further contains taurine and / or a salt thereof. In the ophthalmic composition for anionic SCL of the present invention, taurine and / or a salt thereof are coexisted with the pranoprofen and / or a salt thereof to convert an anionic SCL of pranoprofen and / or a salt thereof. Can be suppressed.

  Taurine is also referred to as aminoethylsulfonic acid, and its chemical name is referred to as 2-aminoethanesulfonic acid. In the ophthalmology field, it is a known compound that is also used for the purpose of promoting the metabolism of the eye.

  The taurine salt is not particularly limited as long as it is pharmaceutically acceptable, and examples thereof include alkali metal salts such as sodium salt and potassium salt. These taurine salts may be used alone or in combination of two or more.

  In the ophthalmic composition for anionic SCL of the present invention, one type may be selected from taurine and its salt, or two or more types may be used in combination. Among taurines and salts thereof, taurine is preferable.

  In the ophthalmic composition for anionic SCL of the present invention, examples of the concentration of taurine and / or a salt thereof include 0.01 to 3 w / v%. In particular, from the viewpoint of more effectively suppressing the adsorption of pranoprofen and / or its salt to anionic SCL, the concentration of taurine and / or its salt is preferably 0.1 to 3 w / v%. More preferably, 0.1-1 w / v% is mentioned.

  The pH of the ophthalmic composition for anionic SCL of the present invention is set to 7.7 or less. In the ophthalmic composition for anionic SCL of the present invention, pranoprofen and / or a salt thereof together with the pranoprofen and / or a salt thereof, and set to such a pH range, It becomes possible to suppress adsorption of the salt to the anionic SCL.

  Moreover, as shown in the test examples to be described later, in the composition containing pranoprofen and / or a salt thereof, when the pH is 4.5 or less, white turbidity caused by pranoprofen and / or a salt thereof is generated. It has been confirmed that if the pH is set to 5.5 or more, a clear appearance property is exhibited. In view of this point, the pH of the ophthalmic composition for anionic SCL of the present invention is clear while further effectively suppressing the adsorption of pranoprofen and / or its salt to the anionic SCL. From the viewpoint of providing appearance properties, it is preferably 5.5 to 7.7, more preferably 6.5 to 7.7, still more preferably 6.5 to 7.4, and most preferably 6.5 to 7. 0 is mentioned.

  In order to adjust the pH of the ophthalmic composition for anionic SCL of the present invention to the above range, a pH adjuster or buffer generally used in ophthalmic compositions may be used. Examples of the pH adjuster include alkalis such as sodium hydroxide and potassium hydroxide; acids such as acetic acid, citric acid, hydrochloric acid, phosphoric acid and tartaric acid. These pH adjusters may be used alone or in combination of two or more. Examples of the buffer include phosphate buffer, borate buffer, citrate buffer, tartaric acid buffer, acetate buffer, amino acid, trometamol, and the like. These buffering agents may be used alone or in combination of two or more.

  The ophthalmic composition for anionic SCL of the present invention may contain a pharmacological component other than pranoprofen and / or a salt thereof, if necessary, in addition to the above components. Examples of such pharmacological components include dipotassium glycyrrhizinate, allantoin, epsilon aminocaproic acid, bromfenac, ketorolac tromethamine, nepafenac, berberine chloride, berberine sulfate, sodium azulene sulfonate, zinc sulfate, zinc lactate, lysozyme hydrochloride Anti-histamines such as chlorpheniramine maleate and diphenhydramine hydrochloride; antiallergic agents such as cromoglycate sodium, ketotifen fumarate, acitazanolast, amlexanox, pemirolast potassium, tranilast, ibudilast; , Ofloxacin, lomefloxacin, levofloxacin, gentamicin, gatifloxacin and other antibacterial agents; ascorbic acid, flavin adenine dinucleotide nato Vitamins such as um, cyanocobalamin, pyridoxine hydrochloride, tocopherol acetate, retinol acetate, retinol palmitate, panthenol, calcium pantothenate, sodium pantothenate; amino acids such as aspartic acid and sodium chondroitin sulfate, neostigmine methyl sulfate Anticholinesterase agents such as salts; vasoconstrictors such as naphazoline, tetrahydrozoline, epinephrine, ephedrine, phenylephrine, dl-methylephedrine; keratoconjunctival epithelial disorders such as sodium hyaluronate; sulfadiazine, sulfisoxazole, sulfisomidine, sulfadimethoxine , Sulfamethoxypyridazine, sulfamethoxazole, sulfaethidol, sulfamethomidine, sulfa Enazoru, sulfaguanidine, phthalidyl Rusuru phosphatidyl azole, sulfa drugs such as succinyl Rusuru phosphatidyl azoles and the like. The compounds exemplified here may be in the form of a salt as long as they are pharmaceutically acceptable, and may be in the form of other salts. These pharmacological components may be used alone or in combination of two or more.

  About the density | concentration of these pharmacological components, it sets suitably according to the use etc. of the kind of pharmacological component, the ophthalmic composition for anionic SCL.

  Further, the ophthalmic composition for anionic SCL of the present invention contains, in addition to the above components, an isotonic agent, a solubilizing agent, a thickener, a chelating agent, a cooling agent, a preservative as necessary. Further, additives such as stabilizers and surfactants may be contained.

  Examples of the isotonic agent include saccharides such as sorbitol, glucose and mannitol; polyhydric alcohols such as glycerin and propylene glycol; salts such as sodium chloride; boric acid and the like. These isotonic agents may be used alone or in combination of two or more.

  Examples of the solubilizer include nonionic surfactants such as polyoxyethylene sorbitan monooleate, polyoxyethylene hydrogenated castor oil, tyloxapol, and pluronic; polyhydric alcohols such as glycerin and macrogol. These solubilizers may be used alone or in combination of two or more.

  Examples of the thickener include water-soluble polymers such as polyvinylpyrrolidone, polyethylene glycol, polyvinyl alcohol, carboxyvinyl polymer, xanthan gum, sodium chondroitin sulfate, sodium hyaluronate; hypromellose, hydroxyethyl cellulose, methyl cellulose, hydroxypropyl cellulose, hydroxypropyl Examples thereof include celluloses such as methyl cellulose and sodium carboxymethyl cellulose. These thickeners may be used alone or in combination of two or more.

  Examples of the chelating agent include edetate, citric acid or a salt thereof. These chelating agents may be used individually by 1 type, and may be used in combination of 2 or more type.

  Examples of the refreshing agent include l-menthol, borneol, camphor, and eucalyptus oil. These refreshing agents may be used alone or in combination of two or more.

  Examples of the preservative include sorbic acid or a salt thereof, benzoic acid or a salt thereof, methyl paraoxybenzoate, ethyl paraoxybenzoate, propyl paraoxybenzoate, chlorobutanol, chlorhexidine gluconate, boric acid, dehydroacetic acid or a salt thereof Benzalkonium chloride, benzethonium chloride, benzyl alcohol, zinc chloride, parachlorometaxylenol, chlorcresol, phenethyl alcohol, polydronium chloride, thimerosal, dibutylhydroxytoluene and the like. These preservatives may be used individually by 1 type, and may be used in combination of 2 or more type.

  Examples of the stabilizer include polyvinyl pyrrolidone, sulfite, monoethanolamine, glycerin, propylene glycol, cyclodextrin, dextran, ascorbic acid, edetate, tocopherol, dibutylhydroxytoluene and the like. These stabilizers may be used individually by 1 type, and may be used in combination of 2 or more type.

  Examples of the surfactant include nonionic surfactants such as tyloxapol, polyoxyethylene hydrogenated castor oil, polyoxyethylene polyoxypropylene block copolymer, polyoxyethylene sorbitan fatty acid ester, octoxynol; alkyldiaminoethylglycine, Amphoteric surfactants such as lauryldimethylaminoacetic acid betaine; anionic surfactants such as alkyl sulfate, N-acyl taurate, polyoxyethylene alkyl ether phosphate, polyoxyethylene alkyl ether sulfate; alkyl pyridinium salts; And cationic surfactants such as alkylamine salts. These surfactants may be used individually by 1 type, and may be used in combination of 2 or more type.

  About the density | concentration of these additives, it sets suitably according to the use etc. of the kind of additive, the ophthalmic composition for anionic SCL.

  The preparation form of the anionic SCL ophthalmic composition of the present invention may be any liquid preparation containing water as a base, and may be any of an aqueous solution, an emulsion, etc., preferably an aqueous solution. Is mentioned.

  The ophthalmic composition for anionic SCL of the present invention may be produced according to a method known per se according to its use, for example, using the method described in the 16th revised Japanese Pharmacopoeia General Rules for Preparations. Can be manufactured.

  The ophthalmic composition for anionic SCL of the present invention is an eye drop that can be instilled even while wearing an anionic SCL (an eye drop for an anionic SCL); an eye wash that can be washed even while wearing an anionic SCL (anionic) SCL eyewash); used as contact lens care products such as anionic SCL mounting solution, anionic SCL multi-purpose solution, anionic SCL cleaning solution, anionic SCL storage solution, and the like. Among these, Preferably, an anionic SCL eye drop, an anionic SCL eye wash, and more preferably an anionic SCL eye drop.

  The anionic SCL to which the present invention is applied is SCL having a polymer containing a monomer containing an anionic group as a constituent material. Anionic SCL includes, for example, SCL composed of a polymer containing an anionic group such as a carboxyl group, a sulfonic acid group, and a phosphoric acid group. More specifically, etafilconA, vifilconA, ocufilcon D, SCL of materials such as methafilconA can be mentioned. The material and manufacturing method of anionic SCL are known.

  Further, the anionic SCL to which the present invention is applied may have either a high water content or a low water content, but preferably a high water content, that is, a group IV (FDA) in the group IV ( Examples thereof include those classified into ionic monomers of 1 mol% or more and water content of 50% or more.

2. Method for inhibiting adsorption of pranoprofen and / or salt thereof to anionic SCL (1)
The present invention also provides taurine and / or a pharmaceutically acceptable salt thereof in an anionic SCL ophthalmic composition containing pranoprofen and / or a pharmaceutically acceptable salt thereof, and Provided is a method for suppressing the adsorption of pranoprofen and / or a salt thereof to anionic SCL, wherein the pH is adjusted to 7.7 or lower. The adsorption inhibiting method is useful for imparting an adsorption inhibiting action of pranoprofen and / or a salt thereof to anionic SCL to an ophthalmic composition for anionic SCL.

  In the adsorption suppression method of the present invention, the type and concentration of pranoprofen and / or its pharmaceutically acceptable salt, the type and concentration of taurine and / or its pharmaceutically acceptable salt, anionic PH of SCL ophthalmic composition, types of pharmacological components and additives to be incorporated into anionic SCL ophthalmic composition, formulation form and use of anionic SCL ophthalmic composition, and target anions The type of ionic SCL and the like are as described in the column of “1. Ophthalmic composition for anionic SCL”.

3. Method for inhibiting adsorption of pranoprofen and / or salt thereof to anionic SCL (2)
The present invention also provides a solution containing pranoprofen and / or a pharmaceutically acceptable salt thereof and taurine and / or a pharmaceutically acceptable salt thereof and having a pH of 7.7 or less. Provided is a method for suppressing adsorption of pranoprofen and / or a salt thereof to anionic SCL, which comprises a step of contacting with sex SCL.

  In the adsorption suppression method of the present invention, the type and concentration of pranoprofen and / or its pharmaceutically acceptable salt, the type and concentration of taurine and / or its pharmaceutically acceptable salt, and the pH of the solution The types of pharmacological ingredients and additives to be mixed in the liquid, the formulation form and use of the liquid, the type of anionic SCL to be applied, etc. are described in “1. Ophthalmic Composition for Anionic SCL”. As described in the column. Moreover, what is necessary is just to set suitably the method of making the said liquid agent contact anionic SCL in the adsorption | suction suppression method of this invention according to the use of the said liquid agent. For example, if the solution is an eye drop, the solution may be applied to the eye with an anionic SCL.

  EXAMPLES The present invention will be specifically described below with reference to examples, but the present invention is not limited to these examples.

Test example 1
The test liquid was prepared by mixing each component shown in Table 1 by a conventional method. While observing the appearance of each of the obtained test solutions, the presence or absence of white turbidity was evaluated by measuring the turbidity (absorbance at 660 nm).

  Moreover, 3 mL of each test solution was put into a vial, 1 piece of SCL was immersed in it, and it shaked at 25 degreeC for 2 hours or more. Further, 3 mL of each test solution was placed in a vial and shaken at 25 ° C. for 2 hours or more without immersing SCL. After shaking, the pranoprofen content in each test solution was measured by liquid chromatography, and the amount of pranoprofen adsorbed on SCL was calculated according to the following formula. When shaking under the condition that SCL is immersed in the test solution, the adsorption of pranoprofen to SCL reaches an equilibrium state within 2 hours. Therefore, if the shaking time is set to 2 hours or more, pranoprofen on SCL is reached. It has been confirmed that there is no effect on the measured value of the amount of adsorbed.

In this test, the following two types of SCL were used, and the amount of pranoprofen adsorbed on each SCL was determined.
Lens 1: Group IV, trade name “One Day Accuview (registered trademark)” (manufactured by Johnson & Johnson Co., Ltd.), anionic, USAN name: etafilcon A
Lens 2: Silicone hydrogel contact lens, Group I, trade name “Air Optics 2 Week (registered trademark)” (Cibavision Co., Ltd.), USAN name: lotrafilcon B

  The obtained results are shown in Table 1. As is clear from the results of Comparative Example 5, it was confirmed that the amount of adsorption of pranoprofen was larger in the anionic SCL than in the nonionic silicone hydrogel contact lens. On the other hand, in the test solutions (Examples 1 to 3) containing pranoprofen and taurine and having a pH of 7.7 or less, adsorption of pranoprofen to the anionic SCL could be remarkably suppressed. In contrast, in the test solutions having pH of 8.0 or more and containing taurine together with pranoprofen (Comparative Examples 2 and 4), the anionic SCL of pranoprofen was compared with the case where taurine was not contained. In addition to not being able to suppress the adsorption to the surface, it was rather encouraged. From the above results, it was revealed that the adsorption of pranoprofen to anionic SCL can be suppressed by containing taurine and / or a salt thereof together with pranoprofen and setting the pH to 7.7 or lower. Further, all the test solutions having a pH of 5.5 or more exhibited a clear appearance property in which no cloudiness was observed.

Test example 2
A test solution was prepared by mixing each component shown in Tables 2 and 3 by a conventional method. While observing the appearance of each of the obtained test solutions, the presence or absence of white turbidity was evaluated by measuring the turbidity (absorbance at 660 nm). For each of the obtained test solutions, the amount of pranoprofen adsorbed on the anionic SCL was measured in the same manner as in Test Example 1.

  The obtained results are shown in Tables 2 and 3. From this result, it was confirmed that the adsorption of pranoprofen to anionic SCL can be suppressed by containing pranoprofen and various concentrations of taurine in combination at pH 5.5 to 7.7. Moreover, in all the test solutions of pH 5.5-7.7, the clear external appearance property which does not recognize white turbidity was exhibited.

Test example 3
A test solution was prepared by mixing each component shown in Table 4 by a conventional method. While observing the appearance of each of the obtained test solutions, the presence or absence of white turbidity was evaluated by measuring the turbidity (absorbance at 660 nm).

  Table 4 shows the obtained results. As apparent from Table 4, when the pH was 4.5 or less, cloudiness was observed in any of the test solutions containing pranoprofen. Based on the results of Test Examples 1 and 2, taurine and / or a salt thereof are contained together with pranoprofen, and the pH is set to 5.5 or more. It became clear that adsorption to anionic SCL can be suppressed.

Claims (8)

An anion comprising pranoprofen and / or a pharmaceutically acceptable salt thereof, taurine and / or a pharmaceutically acceptable salt thereof, and having a pH of 7.7 or less Ophthalmic composition for sexual soft contact lenses (excluding silicone hydrogel contact lenses) .   The ophthalmic composition for anionic soft contact lenses according to claim 1, having a pH of 5.5 to 7.7.   The ophthalmic composition for anionic soft contact lenses according to claim 1 or 2, wherein taurine and / or a pharmaceutically acceptable salt thereof is contained in an amount of 0.01 to 3 w / v%.   The ophthalmic composition for an anionic soft contact lens according to any one of claims 1 to 3, wherein pranoprofen and / or a pharmaceutically acceptable salt thereof is contained in an amount of 0.001 to 0.5 w / v%. .   The ophthalmic composition for an anionic soft contact lens according to any one of claims 1 to 4, which is an eye drop for an anionic soft contact lens. In an ophthalmic composition for anionic soft contact lenses containing pranoprofen and / or a pharmaceutically acceptable salt thereof, taurine and / or a pharmaceutically acceptable salt thereof is blended, and the pH is set to 7. It suppresses adsorption of pranoprofen and / or a pharmaceutically acceptable salt thereof to an anionic soft contact lens (excluding silicone hydrogel contact lenses) , characterized by adjusting to 7 or less Method. Anionic soft contact of a liquid preparation containing pranoprofen and / or a pharmaceutically acceptable salt thereof and taurine and / or a pharmaceutically acceptable salt thereof and having a pH of 7.7 or less Use for the production of ophthalmic compositions for lenses (excluding silicone hydrogel contact lenses) . A solution containing pranoprofen and / or a pharmaceutically acceptable salt thereof and taurine and / or a pharmaceutically acceptable salt thereof and having a concentration of 7.7 or less is applied to an anionic soft contact lens. A method for suppressing adsorption of pranoprofen and / or a pharmaceutically acceptable salt thereof to an anionic soft contact lens, including a step of contacting (except for a method for treating humans) .